The impact of levothyroxine sodium treatment on oxidative stress in Hashimoto's thyroiditis

Ihsan Ates¹, Mustafa Altay², Fatma Meric Yilmaz³, Canan Topcuoglu³, Nisbet Yilmaz¹, Dilek Berker⁴ and Serdar Guler^{4,5}

¹Ankara Numune Training and Research Hospital, Department of Internal Medicine, Ankara, Turkey, ²Kecioren Training and Research Hospital, Department of Internal Medicine, Ankara, Turkey, ³Ankara Numune Training and Research Hospital, Department of Biochemistry, Ankara, Turkey, ⁴Ankara Numune Training and Research Hospital, Department of Endocrinology, Ankara, Turkey and ⁵Hitit University School of Medicine, Department of Endocrinology, Çorum, Turkey

Correspondence should be addressed to I Ates
Email
dr.ihsanates@hotmail.com

Abstract

Objective: Although several studies reported increased oxidative stress in Hashimoto's thyroiditis (HT), the effect of levothyroxine treatment on oxidative status is not studied extensively. Therefore, we conducted this study to investigate the effects of levothyroxine replacement on oxidative stress in HT.

Design and methods: Thirty-six patients recently diagnosed with HT-related hypothyroidism and 36 healthy controls were included in the study. Levothyroxine replacement was started to patients with hypothyroidism, and had been followed-up for 6 months.

Results: Mean basal serum total antioxidant status (TAS), total thiol, arylesterase, and paraoxonase 1 (PON1) levels were significantly lower, and serum total oxidant status (TOS) and oxidative stress index (OSI) were significantly higher in the patients with hypothyroid than the controls. In the hypothyroid group serum TAS, total thiol, arylesterase, and PON1 levels increased and serum TOS and OSI levels decreased significantly after levothyroxine treatment. Pretreatment serum TAS, total thiol, PON1, and arylesterase levels were positively correlated with free levothyroxine (fT₄) and negatively correlated with thyroid-stimulating hormone (TSH), antithyroid peroxidase (anti-TPO), and antithyroglobulin (anti-TG) levels. Also, pretreatment serum TOS and OSI levels were negatively correlated with fT₄ levels and positively correlated with TSH, anti-TPO, and anti-TG. We have also found that the fT₄ and anti-TPO levels are independent predictors of the oxidative stress parameters in stepwise multivariable linear regression analysis.

Conclusion: This study suggests that levothyroxine replacement decreases oxidant status and increases antioxidant status following the 6 months of levothyroxine replacement in hypothyroidism that develops in accordance with the HT.

European Journal of
Endocrinology
(2016) 174, 727–734

Introduction

Hashimoto's thyroiditis (HT), also known as chronic lymphocytic thyroiditis or autoimmune thyroiditis, is an organ-specific autoimmune disease characterized by intrathyroidal mononuclear cell infiltration and formation of antibodies against thyroid-specific antigens namely thyroid peroxidase and thyroglobulin (TG) (1). In this autoimmune thyroiditis, thyroid antibodies cause a decline

in the production of thyroid hormones by increasing the destruction of thyroid follicular cells. As the disease progresses, euthyroidism, subclinical hypothyroidism, and finally overt hypothyroidism are observed (2).

In the last few years, relationship between oxidative stress level and thyroid autoantibodies in HT has attracted a growing interest of researchers. Data from

Clinical Study	I Ates and others	Thyroxine treatment on oxidative stress	174:6	728
----------------	-------------------	---	-------	-----

previous studies suggest that oxidative stress level may be increased due to chronic inflammation (3), deficient thyroid hormone levels (4), excessive autoimmune response, or excessive iodine intake (5) in HT. Reports of higher oxidative stress markers in hypothyroid patients with antithyroid peroxidase (anti-TPO) positivity compared with those without (anti-TPO (-)) (6) and increasing oxidative stress levels by the progression of HT from euthyroid to overt hypothyroid stage (7, 8, 9) also supported previous data. In the light of these studies, it may be suggested that oxidative stress levels may have been increased in hypothyroid stage of HT, where thyroid hormone deficiency is at maximum levels (9). Furthermore, higher oxidative stress levels may also be expected in the existence of autoimmunity at hypothyroid stage (6).

Data are scarce in the literature regarding the effects of levothyroxine replacement on oxidative stress in hypothyroid phase of HT. In addition, these studies have investigated the effects of levothyroxine replacement on only some oxidant radicals and antioxidant enzymes (10, 11). No previous study had investigated the impact of levothyroxine replacement on overall oxidative state, which is defined by total oxidant status (TOS) and total antioxidant status (TAS). Therefore, we conducted this study to analyze the effects of levothyroxine replacement in hypothyroid stage of HT on overall oxidative stress, total thiol, paraoxonase 1 (PON1), and arylesterase.

Patients and methods

Study population

This study was performed prospectively in Internal Medicine and Endocrinology Departments of Ankara Numune Training and Research Hospital, Ankara, between April 2015 and August 2015. After iodination of table salt, Ankara has been one of the sufficient iodine supply regions of Turkey for a long time (12).

Thirty-six patients aged over 18 years, newly diagnosed with hypothyroidism due to HT, and never had been treated for this were included in the study. Age, BMI, and gender-matched 36 healthy volunteers served as the control group.

Patients with known diabetes mellitus, hypertension, other thyroid disease, acute/chronic kidney or liver disease, documented cardiovascular or cerebrovascular disease, malignancy, rheumatic disease, pregnancy, use of vitamin supplements, antioxidant drugs that alter oxidant status, history of smoking, or any amount of alcohol consumption were excluded from the study.

Diagnosis of HT is defined as thyroid antibody (anti-TPO or anti-TG positivity in the serum and the presence of parenchyma heterogeneity in thyroid ultrasonography. Patients who had free thyroxine (fT₄) levels below normal range (0.9–1.7 ng/dL) and thyroid-stimulating hormone (TSH) levels above normal range (0.5–4 µIU/mL) are considered to have overt hypothyroidism. After the diagnosis, patients with hypothyroid were started on levothyroxine replacement, titrating the daily dose according to TSH level. Patients were informed about optimal use and storage of levothyroxine tablets.

BMI was calculated by dividing body weight with the square of height in meters (BMI = kg/m²).

The study protocol was conducted in accordance with the Helsinki Declaration 2013 Brazil version and was approved by the Local Ethics Research Committee. All subjects provided written informed consent before participation in the study.

Blood sample collection

Venous serum samples were obtained from the patient group at baseline and 6 months after the initiation of levothyroxine treatment (euthyroid stage). Venous serum samples of healthy controls were obtained only once at the time they were included in the study. Five milliliter blood sample was obtained from each subject in the patient and control groups after 12 h of overnight fasting, between 0800 and 0900 h for the assessment of oxidative stress parameters. After the centrifugation for 10 min at 1500 g serum samples were separated into Eppendorf tubes and stored at –80°C until assay. All samples are defrosted and assayed once and simultaneously.

Biochemical assays

Total cholesterol, HDL-cholesterol, and triglyceride levels were measured by colorimetric enzymatic method using Hitachi Modular P800 (Roche Diagnostics) analyzer. LDL-cholesterol was calculated by the method by Friedewald *et al.* (13). TSH, fT₄, anti-TPO (normal range: 0–34 IU/mL), and anti-TG (normal range: 0–115 IU/mL) levels were measured by electroluminescence immunoassay method in Cobas E601 (Roche Diagnostics) analyzer.

Oxidative stress parameters

There are lots of molecules that reflect the oxidant and antioxidant status of the body. TAS and TOS reflect the

general status of the oxidative stress in the body. Total thiol is an antioxidant that can react with free radicals in order to protect against tissue and cell damage, which is caused by reactive oxygen species. The arylesterase and PON1 are serum arylesterase enzymes that are closely bound to HDL-cholesterol, which protects LDL-cholesterol against oxidative damage. Oxidative stress index (OSI) is an indicative parameter of the degree of oxidative stress.

Measurement of total antioxidant status

Serum TAS levels were measured by colorimetric method using a commercially available kit (Rel Assay Diagnostics, Gaziantep, Turkey, REF No: RL0024, LOT No: JE 14048Og). The results were expressed in mmol Trolox Eq./L.

Measurement of total oxidant status

Serum TOS levels were measured by colorimetric method using a commercially available kit (Rel Assay Diagnostics, Gaziantep, Turkey, REF No: RL0017, LOT No: JE 14042A). The results were expressed in μmol hydrogen peroxide (H_2O_2) Eq./L.

Measurement of total thiol

Serum total thiol levels were measured by colorimetric method using a commercially available kit (Rel Assay Diagnostics, Gaziantep, Turkey, REF No: RL0178, LOT No: AL 13011TL). The results were expressed in mmol/L.

Measurement of PON1

Serum PON1 levels were measured by colorimetric method using a commercially available kit (Rel Assay Diagnostics, Gaziantep, Turkey, REF No: RL0031, LOT No: JE14028P). The results were expressed in U/L.

Measurement of arylesterase

Serum arylesterase levels were measured by colorimetric method using a commercially available kit (Rel Assay Diagnostics, Gaziantep, Turkey, REF No: RL0055, LOT No: JR13017AR). The results were expressed in U/L.

Oxidative stress index

The OSI value was calculated according to the following formula: $\text{OSI (arbitrary unit)} = \text{TOS } (\mu\text{mol H}_2\text{O}_2 \text{ Eq./L}) / \text{TAS (mmol Trolox Eq./L)}$ (14).

Thyroid ultrasonography

Thyroid ultrasonography was performed by one radiologist using Logiq 7 (GE Health Medical) ultrasound machine with a 7.5 MHz probe. Thyroiditis was diagnosed by the presence of heterogeneity in thyroid parenchyma.

Statistical analysis

Statistical analysis was carried out using SPSS for Windows version 20. Normal distribution was evaluated by Kolmogorov–Smirnov test. Numerical parameters were presented as mean $\pm$ s.d. or median (min–max). Categorical variables were expressed as numbers and percentage. Comparison between the control patients and pretreatment patients with hypothyroidism or pre- and post-treatment patients with hypothyroidism was done by Student's *t*-test or Mann–Whitney U test. Changes in the laboratory findings of patients with hypothyroidism before and after treatment were analyzed using paired-samples *t*-test. The stepwise linear regression analysis was used for the detection of risk factors affecting oxidative stress levels. The stepwise logistic regression analysis was used

Table 1 Comparison of characteristics and laboratory findings of pretreatment patients with hypothyroidism (HT) and control group. Numerical variables were expressed as mean $\pm$ s.d. or median (min–max).

Variables	HT pretreatment <i>n</i> = (36)	Control <i>n</i> = (36)	<i>P</i> -value
Gender, male, <i>n</i> (%)	9 (25.0)	9 (25.0)	0.999
Age (years)	41.4 $\pm$ 13.9	41.3 $\pm$ 8.8	0.978
BMI (kg/m ²)	28.4 $\pm$ 5.9	28.1 $\pm$ 4.1	0.903
TSH ($\mu\text{IU/mL}$)	12.9 (6.6–100)	1.7 (0.5–3.5)	<0.001*
fT ₄ (ng/dL)	0.7 (0.1–0.8)	1.1 (0.9–1.5)	<0.001*
Anti-TG (IU/mL)	325.4 (10–4000)	11.5 (4–95.2)	<0.001*
Anti-TPO (IU/mL)	226.2 (9–1000)	8.2 (4–20.6)	<0.001*
Total cholesterol (mg/dL)	217.8 $\pm$ 46.8	188.8 $\pm$ 29.9	0.003*
Triglyceride (mg/dL)	109 (49–346)	100 (39–280)	0.999
LDL (mg/dL)	105.2 $\pm$ 21.6	100.7 $\pm$ 24.2	0.408
HDL (mg/dL)	48.3 $\pm$ 12.1	54.4 $\pm$ 15.5	0.223
TAS (mmol Trolox Eq./L)	1.5 $\pm$ 0.3	1.7 $\pm$ 0.2	<0.001*
TOS ($\mu\text{mol H}_2\text{O}_2$ Eq./L)	6.3 $\pm$ 1.8	4.8 $\pm$ 1.6	0.036*
OSI (arbitrary unit)	4.4 $\pm$ 0.9	2.8 $\pm$ 0.9	0.002*
Total thiol (mmol/L)	440.4 $\pm$ 87.9	490.3 $\pm$ 74.6	0.039*
Arylesterase (U/L)	1098.6 $\pm$ 156.6	1323.1 $\pm$ 211.2	<0.001*
PON1 (U/L)	432.8 $\pm$ 62.9	466.0 $\pm$ 31.4	0.020*

**P* < 0.05 statistical significance.

Clinical Study	I Ates and others	Thyroxine treatment on oxidative stress	174:6	730
----------------	-------------------	---	-------	-----

Table 2 Comparison of laboratory findings of pre- and post-treatment patients with hypothyroidism. Numerical variables were expressed as mean $\pm$ s.d. or median (min–max).

Variables	Hypothyroidism		P-value
	Pretreatment <i>n</i> =(36)	Post-treatment <i>n</i> =(36)	
TSH (μ IU/mL)	12.9 (6.6–100)	2.3 (0.4–4.4)	<0.001*
fT ₄ (ng/dL)	0.7 (0.1–0.8)	1.1 (0.9–1.7)	<0.001*
Anti-TG (IU/mL)	325.4 (10–4000)	126.8 (20–656)	<0.001*
Anti-TPO (IU/mL)	226.2 (9–1000)	105 (1.7–350.0)	<0.001*
Total cholesterol (mg/dL)	217.8 $\pm$ 46.8	170.8 $\pm$ 30.2	<0.001*
Triglyceride (mg/dL)	109 (49–346)	108 (33–356)	0.999
LDL (mg/dL)	105.2 $\pm$ 21.6	99.3 $\pm$ 25.1	0.289
HDL (mg/dL)	48.3 $\pm$ 12.1	51.6 $\pm$ 15.8	0.885
TAS (mmol Trolox Eq./L)	1.5 $\pm$ 0.3	1.7 $\pm$ 0.2	<0.001*
TOS (μ mol H ₂ O ₂ Eq./L)	6.3 $\pm$ 1.8	4.4 $\pm$ 1.3	0.007*
OSI (arbitrary unit)	4.4 $\pm$ 0.9	2.6 $\pm$ 0.7	<0.001*
Total thiol (mmol/L)	440.4 $\pm$ 87.9	496.0 $\pm$ 103.3	0.028*
Arylesterase (U/L)	1098.6 $\pm$ 156.6	1247.5 $\pm$ 257.9	0.011*
PON1 (U/L)	432.8 $\pm$ 62.9	470.8 $\pm$ 53.2	0.006*

**P*<0.05 statistical significance.

for the detection of risk factors affecting hypothyroidism. A *P* value of <0.05 was considered to be significant for statistical analyses.

Results

Table 1 summarizes the characteristics and laboratory findings of pretreatment patients with hypothyroidism and control group. Seventy-two subjects, 36 patients with hypothyroidism (9 males, 27 females; mean age: 41.4 $\pm$ 13.9 years), and 36 healthy controls (9 males, 27 females; mean age: 41.3 $\pm$ 8.8 years) were included in the study.

The two groups were similar with regard to sex, age, and BMI (*P*>0.05). Basal TSH (*P*<0.001), anti-TPO (*P*<0.001), anti-TG (*P*<0.001), and total cholesterol levels (*P*=0.003) were significantly higher and fT₄ level (*P*<0.001) was significantly lower in pretreatment hypothyroid group than the control group.

Basal TOS and OSI ratio were significantly higher (*P*=0.036 and *P*=0.002, respectively) and basal arylesterase, TAS, total thiol, and PON1 levels were

significantly lower (*P*<0.001, *P*<0.001, *P*=0.039, and *P*=0.020, respectively) than the healthy controls.

Effect of levothyroxine treatment

Table 2 summarizes laboratory findings of pre- and post-treatment patients with hypothyroidism. All patients were found to have normalized TSH and fT₄ levels after 6 months of levothyroxine replacement. Post-treatment median anti-TPO and anti-TG levels were lower compared with pretreatment levels (*P*_{pre-post}<0.001). Mean total cholesterol level decreased significantly after the treatment (*P*_{pre-post}<0.001). There was no statistically significant difference between groups regarding other lipid parameters (*P*>0.05). With levothyroxine treatment mean TOS and OSI ratio significantly decreased (6.3 $\pm$ 1.8 vs 4.4 $\pm$ 1.3, *P*=0.007 and 4.4 $\pm$ 0.9 vs 2.6 $\pm$ 0.7, *P*<0.001, respectively). Levothyroxine treatment resulted in significant increases in arylesterase (from 1098.6 $\pm$ 156.6 to 1247.5 $\pm$ 257.9, *P*=0.011), TAS (from 1.5 $\pm$ 0.3 to 1.7 $\pm$ 0.2, *P*<0.001), total thiol (from 440.4 $\pm$ 87.9 to 496.0 $\pm$ 103.3, *P*=0.028), and PON1 (from 432.8 $\pm$ 62.9 to 470.8 $\pm$ 53.2, *P*=0.006) levels. Mean or median post-treatment levels of all these parameters were similar between the patients and the controls (*P*>0.05 for all).

In the pretreatment patients with HT, the correlation analysis between oxidative stress parameters and other laboratory parameters is shown in Table 3. Pretreatment TAS (*r*=0.575, *P*=0.001), (*r*=−0.344, *P*=0.028), (*r*=−0.546, *P*=0.003), (*r*=−0.503, *P*=0.001), respectively), total thiol (*r*=0.470, *P*=0.010), (*r*=−0.375, *P*=0.018), (*r*=−0.465, *P*=0.003), (*r*=−0.394, *P*=0.007), respectively), PON1 (*r*=0.510, *P*=0.001), (*r*=−0.340, *P*=0.022), (*r*=−0.478, *P*=0.004), (*r*=−0.390, *P*=0.008), respectively), and arylesterase levels (*r*=0.520, *P*=0.005), (*r*=−0.388, *P*=0.009), (*r*=−0.503, *P*=0.003), (*r*=−0.418, *P*=0.009), respectively) were found to be positively correlated with fT₄ and negatively correlated with TSH, anti-TPO, and anti-TG levels. Also, pretreatment TOS (*r*=−0.539, *P*=0.001), (*r*=0.350, *P*=0.002), (*r*=0.467, *P*=0.004), (*r*=0.406, *P*=0.006), respectively) and OSI (*r*=−0.554, *P*=0.001), (*r*=0.377, *P*=0.017), (*r*=0.486, *P*=0.001), (*r*=0.446, *P*=0.007), respectively) levels were negatively correlated with fT₄ levels and positively correlated with TSH, anti-TPO, and anti-TG.

In stepwise multivariable linear regression analysis, fT₄ and anti-TPO levels were found to be independent predictors of the OSI, TAS, TOS, total thiol, PON1, and arylesterase before the treatment. In stepwise multivariable logistic regression analysis, TSH, anti-TPO,

Clinical Study	I Ates and others	Thyroxine treatment on oxidative stress	174:6	731
----------------	-------------------	---	-------	-----

Table 3 Relationship between the oxidative stress parameters levels and other laboratory parameters before the treatment in patients with HT.

Variables	TAS		TOS		Total thiol		Arylesterase		PON1		OSI	
	<i>r</i>	<i>P</i> -value	<i>r</i>	<i>P</i> -value	<i>r</i>	<i>P</i> -value	<i>r</i>	<i>P</i> -value	<i>r</i>	<i>P</i> -value	<i>r</i>	<i>P</i> -value
TSH	−0.344	0.028*	0.350	0.002*	−0.375	0.018*	−0.388	0.009*	−0.340	0.022*	0.377	0.017*
fT ₄	0.575	0.001*	−0.539	0.001*	0.470	0.010*	0.520	0.005*	0.510	0.001*	−0.554	0.001*
Anti-TPO	−0.546	0.003*	0.467	0.004*	−0.465	0.003*	−0.503	0.003*	−0.478	0.004*	0.486	0.001*
Anti-TG	−0.503	0.001*	0.406	0.006*	−0.394	0.007*	−0.418	0.009*	−0.390	0.008*	0.446	0.007*

**P* < 0.05 statistical significance.

OSI, and arylesterase levels were found to be independent predictors of hypothyroidism (Table 4).

Discussion

To our knowledge, this is the first study to demonstrate increased TAS, total thiol, PON1, and arylesterase and decreased TOS and OSI levels following levothyroxine replacement in patients with HT.

In our study, we found that TOS and OSI levels were higher, while TAS levels were lower in patients with HT before levothyroxine replacement compared with controls. Oxidative stress develops as a result of insufficiency of antioxidant mechanisms against increased oxidant radicals. Higher oxidative stress levels in patients with hypothyroid due to HT compared with those unrelated to HT and healthy controls were previously demonstrated by various studies (6, 10, 15, 16). For instance, Nanda *et al.* (6) reported higher oxidative stress levels in anti-TPO (+) patients with hypothyroid compared with anti-TPO (−) patients with hypothyroid. Three different studies also had reported higher oxidative stress levels in HT compared with healthy controls, supporting our data (4, 9, 10, 16).

High level of oxidative stress in HT might be due to a variety of reason. The most plausible reason would be chronic inflammation causing high oxidative stress. It is thought that T and B lymphocytes play an active role in the pathogenesis of HT, and may cause an increase in reactive oxygen radicals by activating NADPH oxidase (NOX) enzyme (3, 17). Indeed, this had been proven in wildtype mice by the demonstration of increase in H₂O₂ and superoxide anions in T cells via the stimulation of T cell receptors by antigens or mitogens (18). Another reason of high oxidative stress in HT might be deficiency of thyroid hormones (15). Thyroid hormones are thought to contribute to free oxygen radical cleaning by increasing nonenzymatic antioxidant molecules (19) which affect antioxidant enzyme levels such as superoxide dismutase, catalase, and glutathione peroxidase (20), and cause the stimulation of mitochondrial uncoupling proteins which

are nonenzymatic antioxidant molecules (21). Lastly, high oxidative stress in HT might be due to excessive iodine intake and autoimmune response. H₂O₂ which is an oxidant radical is needed for the oxidation of iodide during thyroid hormone synthesis in thyroid epithelial cells. High iodine intake causes excessive H₂O₂ production. In this case, oxidant radicals start to rise in the body (22). Excessive autoimmune response is also thought to increase oxidative stress by exaggerating inflammation or causing a decrease in thyroid hormone synthesis by increasing tissue injury.

In the light of these data, we have thought to investigate the effect of levothyroxine replacement on oxidative stress in hypothyroid patients with HT. There are only a few studies in the literature to demonstrate impacts of levothyroxine replacement on oxidant and antioxidant molecules. Baskol *et al.* (10) reported a decrease in malondialdehyde (MDA) and increase in PON and superoxide dismutase levels after 6 months of levothyroxine replacement. Similarly, a decrease in MDA levels after 2 months of levothyroxine replacement was demonstrated by Erdamar *et al.* (23). However, both studies have only investigated the effects of levothyroxine replacement on oxidant and antioxidant molecules, and had not evaluated the overall oxidative stress in the body.

In our study, post-treatment TAS, total thiol, PON1, and arylesterase levels were higher and TOS and OSI levels were lower compared with pretreatment levels. Increase in TAS levels and decrease in TOS levels after levothyroxine replacement can be explained by a few mechanisms. One explanation would be levothyroxine replacement causing a decrease in chronic inflammation, which plays an important role in HT. Previous studies showed decreased TNF- α , interleukin (IL)-1 β , IL-6, and monocyte chemoattractant protein-1 levels in euthyroid group (24), decreased intercellular adhesion molecule-1 levels in subclinical hypothyroid group (25), and decreased C-reactive protein levels in another subclinical hypothyroid group after levothyroxine replacement (26). In addition, levothyroxine replacement has also been shown to decrease

Clinical Study	I Ates and others	Thyroxine treatment on oxidative stress	174:6	732
----------------	-------------------	---	-------	-----

Table 4 The determination of independent predictors of oxidative stress parameters and hypothyroidism with stepwise regression analysis.

	$\beta \pm \text{S.E.M.}$	OR	R^2	P-value	95% CI		P-value
					Lower	Upper	
Stepwise linear regression model†							
TAS			0.596	<0.001			
ft4	0.565±0.076				0.325	0.805	0.002*
Anti-TPO	−0.471±0.097				−0.721	−0.221	0.005*
TOS			0.649	0.001			
ft4	−0.881±0.100				−1.101	−0.660	<0.001*
Anti-TPO	0.782±0.245				0.244	1.321	0.008*
Total thiol			0.641	0.002			
ft4	0.890±0.287				0.287	1.494	0.006*
Anti-TPO	−0.719±0.223				−1.186	−0.251	0.005*
Arylesterase			0.627	0.001			
ft4	0.992±0.322				0.319	1.665	0.006*
Anti-TPO	−0.885±0.169				−1.239	−0.531	0.001*
PON1							
ft4	0.623±0.168		0.594	0.001	0.271	0.974	0.001*
Anti-TPO	−0.409±0.061				−2.006	−0.294	0.011*
OSI							
ft4	−0.780±0.283		0.643	<0.001	−1.380	−0.185	0.013*
Anti-TPO	0.699±0.249				0.177	1.220	0.011*
Stepwise logistic regression model†							
Hypothyroidism							
TSH		9.190	0.857	<0.001	1.460	37.857	0.018*
Anti-TPO		1.320			1.051	1.658	0.017*
OSI		2.660			1.429	4.951	0.002*
Arylesterase		0.990			0.984	0.998	0.003*

* $P < 0.05$ statistical significance. †Stepwise linear regression model was done using age, sex, BMI, TSH, ft₄, anti-TG, anti-TPO, total cholesterol, triglyceride, LDL, and HDL as risk factors. Before regression analysis, logarithmical transformation was performed on TSH, ft₄, anti-TG, and anti-TPO. ‡Stepwise logistic regression model was done using TSH, ft₄, anti-TG, anti-TPO, total cholesterol, TAS, TOS, OSI, total thiol, arylesterase, and PON1 as risk factors. β , unstandardized coefficients.

lymphocyte infiltration in rats and cats with HT (27, 28). Increase of reactive oxygen molecules by NOX enzyme during chronic inflammation was previously reported (3, 17). In our study, since no inflammation marker was tested, contribution of decreased chronic inflammation to decreased oxidative stress cannot be evaluated. However, decreased post-treatment thyroid antibody levels in our study may indirectly indicate a decrease in chronic inflammation.

The second factor affecting decreased oxidative stress in our study may be increase in levels of thyroid hormones. Thyroid hormones had been shown to remove free oxygen radicals by increasing levels of enzymatic and nonenzymatic antioxidant molecules, thereby decreasing the oxidative stress (19, 20, 21). Baskol *et al.* reported increase in levels of superoxide dismutase enzyme, which plays a role in removal of oxygen radicals, after levothyroxine replacement compared with superoxide dismutase enzyme level before treatment. Supporting these data, we have shown an increase in the levels of antioxidant enzymes, namely PON1 and arylesterase, compared with pretreatment levels. Moreover, we have also demonstrated

that increase in ft₄ levels is an independent factor for the increase in TAS and decrease in TOS and OSI levels. In summary, our results suggest that thyroid replacement therapy has a decreasing effect on oxidative stress.

Furthermore, we have also determined that anti-TPO level is an independent risk factor for oxidative stress. Several previous studies reported decreased thyroid antibody levels following levothyroxine replacement (29, 30, 31). Increased TSH levels had been shown to increase autoantibody levels by stimulating lymphocytes (29). In addition, high levels of TSH may also increase thyroid antigen levels, therefore, antibody levels might increase *via* an indirect effect (32). After levothyroxine replacement, when TSH levels decrease, antibody levels also decrease due to a decline in both lymphocyte induction rate and formation of thyroid-specific antigens. Thus, a decrease in autoantibody levels may be an indirect indicator of decreased chronic inflammation.

In this study, we have found that the ft₄ and anti-TPO levels are independent predictors of the oxidative stress parameters in stepwise multivariable linear

regression analysis. In the case of thyroid hormone deficiency, glutathione peroxidase (GPX), which is responsible for the removal of oxidant radicals by a reaction with thiol compounds, starts to increase as a protective mechanism. Increased GPX decreases total thiol reserves by causing oxidation of thiol compounds (5). Glutathione reductase (GR) is an enzyme that is responsible for the reduction of oxidated thiol compounds. It has been reported in a study on rats that GR levels decreased at the 30th day, and GPX levels increased at the 90th day of levothyroxine replacement (33). In the light of these data, we may assume that decreased total thiol levels in our study may be due to decreased GPX and increased GR levels.

Post-treatment increase of arylesterase enzyme levels in our study may be due to both decreased oxidant radicals and decrease of total cholesterol levels following therapy. An increase in oxidant radicals (10) and cholesterol levels (34) had been previously reported to decrease PON levels.

The major limitations of this study include the lack of an inflammatory marker and lack of urine iodine analysis to confirm excessive intake of iodine, small sample size, and the cross-sectional nature of the study.

In conclusion, our data suggest that levothyroxine replacement decreases oxidant status and increases antioxidant status. This condition urges us to consider that lack of thyroid hormone may be effective in increasing the oxidative stress of patients with hypothyroid. In the logistic regression analysis, determination of OSI as an independent risk factor for the hypothyroidism also supports this fact. Further studies are required in order to justify whether the oxidative stress is a cause or result of hypothyroidism.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This study did not receive any specific grant from any funding agency in the public, commercial, or nonprofit sectors.

Author contribution statement

I A, M A, and S G: conception, design, and manuscript writing. F M Y and C T: laboratory analysis. All authors contributed to data collection and data interpretation, and approved the manuscript.

References

- Dayan CM & Daniels GH. Chronic autoimmune thyroiditis. *New England Journal of Medicine* 1996 **335** 99–107. (doi:10.1056/NEJM199607113350206)
- Pearce EN, Farwell AP & Braverman LE. Thyroiditis. *New England Journal of Medicine* 2003 **348** 2646–2655.
- Jackson SH, Devadas S, Kwon J, Pinto LA & Williams MS. T cells express a phagocyte-type NADPH oxidase that is activated after T cell receptor stimulation. *Nature Immunology* 2004 **5** 818–827. (doi:10.1038/ni1096)
- Baser H, Can U, Baser S, Yerlikaya FH, Aslan U & Hidayetoglu BT. Assessment of oxidative status and its association with thyroid autoantibodies in patients with euthyroid autoimmune thyroiditis. *Endocrine* 2015 **48** 916–923. (doi:10.1007/s12020-014-0399-3)
- Rostami R, Aghasi MR, Mohammadi A & Nourooz-Zadeh J. Enhanced oxidative stress in Hashimoto's thyroiditis: inter-relationships to biomarkers of thyroid function. *Clinical Biochemistry* 2013 **46** 308–312. (doi:10.1016/j.clinbiochem.2012.11.021)
- Nanda N, Bobby Z & Hamide A. Oxidative stress in anti thyroperoxidase antibody positive hypothyroid patients. *Asian Journal of Biochemistry* 2012 **7** 54–58. (doi:10.3923/ajb.2012.54.58)
- Ozturk U, Vural P, Ozderya A, Karadag B, Dogru-Abbasoglu S & Uysal M. Oxidative stress parameters in serum and low density lipoproteins of Hashimoto's thyroiditis patients with subclinical and overt hypothyroidism. *International Immunopharmacology* 2012 **14** 349–352. (doi:10.1016/j.intimp.2012.08.010)
- Reddy VS, Gouraju S, Suchitra MM, Suresh V, Sachan A, Srinivasa Rao PV & Bitla AR. Antioxidant defense in overt and subclinical hypothyroidism. *Hormone and Metabolic Research* 2013 **45** 754–758. (doi:10.1055/s-00000025)
- Ates I, Yilmaz FM, Altay M, Yilmaz N, Berker D & Guler S. The relationship between oxidative stress and autoimmunity in Hashimoto's thyroiditis. *European Journal of Endocrinology* 2015 **173** 791–799. (doi:10.1530/EJE-15-0617)
- Baskol G, Atmaca H, Tanriverdi F, Baskol M, Kocer D & Bayram F. Oxidative stress and enzymatic antioxidant status in patients with hypothyroidism before and after treatment. *Experimental and Clinical Endocrinology & Diabetes* 2007 **115** 522–526.
- Azizi F, Raiszadeh F, Solati M, Etemadi A, Rahmani M & Arabi M. Serum paraoxonase 1 activity is decreased in thyroid dysfunction. *Journal of Endocrinological Investigation* 2003 **26** 703–709. (doi:10.1007/BF03347350)
- Erdogan ME, Agbaht K, Altunsu T, Ozbas S, Yucesan F, Tezel B, Sargin C, Ilbeg I, Artik N, Kose R *et al.* Current iodine status in Turkey. *Journal of Endocrinological Investigation* 2009 **32** 617–622. (doi:10.1007/BF03346519)
- Friedewald WT, Levy RI & Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clinical Chemistry* 1972 **18** 499–502.
- Ulas T, Buyukhatipoglu H, Kirhan I, Dal MS, Ulas S, Demir ME, Eren MA, Ucar M, Hazar A, Kurkuoglu IC *et al.* Evaluation of oxidative stress parameters and metabolic activities of nurses working day and night shifts. *Revista da Escola de Enfermagem da USP* 2013 **47** 471–476.
- Baser H, Can U, Baser S, Yerlikaya FH, Aslan U & Hidayetoglu BT. Assessment of oxidative status and its association with thyroid autoantibodies in patients with euthyroid autoimmune thyroiditis. *Endocrine* 2014 **48** 916–923.
- Wang D, Feng JF, Zeng P, Yang YH, Luo J & Yang YW. Total oxidant/antioxidant status in sera of patients with thyroid cancers. *Endocrine-Related Cancer* 2011 **18** 773–782. (doi:10.1530/ERC-11-0230)
- Bedard K & Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. *Physiological Reviews* 2007 **87** 245–313. (doi:10.1152/physrev.00044.2005)
- Devadas S, Zaritskaya L, Rhee SG, Oberley L & Williams MS. Discrete generation of superoxide and hydrogen peroxide by T cell receptor stimulation: selective regulation of mitogen-activated protein kinase

Clinical Study	I Ates and others	Thyroxine treatment on oxidative stress	174:6	734
----------------	-------------------	---	-------	-----

- activation and fas ligand expression. *Journal of Experimental Medicine* 2002 **195** 59–70. (doi:10.1084/jem.20010659)
- 19 Venditti P, Balestrieri M, Di Meo S & De Leo T. Effect of thyroid state on lipid peroxidation, antioxidant defences, and susceptibility to oxidative stress in rat tissues. *Journal of Endocrinology* 1997 **155** 151–157. (doi:10.1677/joe.0.1550151)
 - 20 Fernandez V, Llesuy S, Solari L, Kipreos K, Videla LA & Boveris A. Chemiluminescent and respiratory responses related to thyroid hormone-induced liver oxidative stress. *Free Radical Research Communications* 1988 **5** 77–84. (doi:10.3109/10715768809066914)
 - 21 Rousset S, Alves-Guerra MC, Mozo J, Miroux B, Cassard-Doulcier AM, Bouillaud F & Ricquier D. The biology of mitochondrial uncoupling proteins. *Diabetes* 2004 **53** (Supplement 1) S130–S135.
 - 22 Burek CL & Rose NR. Autoimmune thyroiditis and ROS. *Autoimmunity Reviews* 2008 **7** 530–537. (doi:10.1016/j.autrev.2008.04.006)
 - 23 Erdamar H, Demirci H, Yaman H, Erbil MK, Yakar T, Sancak B, Elbeg S, Biberoglu G & Yetkin I. The effect of hypothyroidism, hyperthyroidism, and their treatment on parameters of oxidative stress and antioxidant status. *Clinical Chemistry and Laboratory Medicine* 2008 **46** 1004–1010.
 - 24 Krysiak R & Okopien B. The effect of levothyroxine and selenomethionine on lymphocyte and monocyte cytokine release in women with Hashimoto's thyroiditis. *Journal of Clinical Endocrinology & Metabolism* 2011 **96** 2206–2215.
 - 25 Kowalska I, Borawski J, Nikolajuk A, Budlewski T, Otziomek E, Gorska M & Straczowski M. Insulin sensitivity, plasma adiponectin and sICAM-1 concentrations in patients with subclinical hypothyroidism: response to levothyroxine therapy. *Endocrine* 2011 **40** 95–101. (doi:10.1007/s12020-011-9446-5)
 - 26 Velija-Asimi Z & Karamelic J. The effects of treatment of subclinical hypothyroidism on metabolic control and hyperinsulinemia. *Medical Archives* 2007 **61** 20–21.
 - 27 Reinhardt W, Paul TL, Allen EM, Alex S, Yang YN, Appel MC & Braverman LE. Effect of L-thyroxine administration on the incidence of iodine induced and spontaneous lymphocytic thyroiditis in the BB/Wor rat. *Endocrinology* 1988 **122** 1179–1181.
 - 28 Schumm-Draeger PM & Fortmeyer HP. Autoimmune thyroiditis – spontaneous disease models – cat. *Experimental and Clinical Endocrinology & Diabetes* 1996 **104** (Supplement 3) 12–13; discussion 14–16.
 - 29 Romaldini JH, Biancalana MM, Figueiredo DI, Farah CS & Mathias PC. Effect of L-thyroxine administration on antithyroid antibody levels, lipid profile, and thyroid volume in patients with Hashimoto's thyroiditis. *Thyroid* 1996 **6** 183–188.
 - 30 Aksoy DY, Kerimoglu U, Okur H, Canpinar H, Karaagaoglu E, Yetgin S, Kansu E & Gedik O. Effects of prophylactic thyroid hormone replacement in euthyroid Hashimoto's thyroiditis. *Endocrine Journal* 2005 **52** 337–343. (doi:10.1507/endocrj.52.337)
 - 31 Padberg S, Heller K, Usadel KH & Schumm-Draeger PM. One-year prophylactic treatment of euthyroid Hashimoto's thyroiditis patients with levothyroxine: is there a benefit? *Thyroid* 2001 **11** 249–255. (doi:10.1089/105072501750159651)
 - 32 Chiovato L, Vitti P, Lombardi A, Kohn LD & Pinchera A. Expression of the microsomal antigen on the surface of continuously cultured rat thyroid cells is modulated by thyrotropin. *Journal of Clinical Endocrinology & Metabolism* 1985 **61** 12–16.
 - 33 Saicic ZS, Mijalkovic DN, Nikolic AL, Blagojevic DP & Spasic MB. Effect of thyroxine on antioxidant defense system in the liver of different aged rats. *Physiological Research* 2006 **55** 561–568.
 - 34 Al-Rejaie SS, Aleisa AM, Sayed-Ahmed MM, Al-Shabanah OA, Abuhashish HM, Ahmed MM, Al-Hosaini KA & Hafez MM. Protective effect of rutin on the antioxidant genes expression in hypercholesterolemic male Westar rat. *BMC Complementary and Alternative Medicine* 2013 **13** 136. (doi:10.1186/1472-6882-13-136)

Received 29 October 2015

Revised version received 22 February 2016

Accepted 7 March 2016